Amarin Corp Plc (AMRN)

[Jamaalish]

Most Frequent Treatment-Emergent Adverse Events: ≥5% in Either TreatmentGroup and Significantly Different


Preferred Term VASCEPA (N=4089) Placebo (N=4090) P-value

Diarrhea 367 (9.0%) 453 (11.1%) 0.002

Peripheral edema 267 (6.5%) 203 (5.0%) 0.002

Constipation 221 (5.4%) 149 (3.6%) <0.001

Atrial fibrillation 215 (5.3%) 159 (3.9%) 0.003

Anemia 191 (4.7%) 236 (5.8%) 0.03